Diagens Biotechnology News and Activities

Diagens Biotechnology is a company listed under the stock ticker 02526 (CN).

Acquisition, funding and merger involving Diagens Biotechnology.

• Diagens Biotechnology has just announced a $101 Million fundraising (posted on March 31 2026).

View the org chart displaying its 8 main executives

Most searched biographies at Diagens Biotechnology

• Ning Song, Chief Executive Officer
• Jing Zhang, Director
• Zong Yao Song, Director

Create your alert
to follow the executive moves at Diagens Biotechnology.

Diagens Biotechnology has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Diagens Biotechnology

Social media about Diagens Biotechnology

• Diagens Biotechnology on Wikipedia, Google News & Yahoo Finance
• Diagens Biotechnology on LinkedIn, X (Twitter) & YouTube